China Manufacturing Landscape for Maropitant (CAS 147116-67-4)
China has established itself as the world’s leading production hub for veterinary pharmaceutical active ingredients, and Maropitant citrate is no exception. As a China-based quality-certified manufacturer, we operate at the intersection of advanced synthetic chemistry capability and cost-efficient large-scale production. Our facility in Hebei Province is purpose-built for the synthesis of complex neurokinin-1 (NK1) receptor antagonist compounds, positioning us as a preferred source for global veterinary pharmaceutical companies seeking reliable, competitively priced Maropitant API.
The Chinese veterinary API sector has undergone significant transformation over the past decade, with manufacturers investing heavily in facility upgrades, quality management systems, and regulatory compliance. Our company exemplifies this evolution — we have transitioned from basic intermediate production to full quality-controlled API manufacturing with complete backward integration of key starting materials, ensuring consistent supply and quality control from raw material sourcing through final product release.
Manufacturing Process & Facility
Our Maropitant manufacturing process employs a proprietary multi-step synthesis route starting from commercially available quinuclidine derivatives. The synthesis involves chiral resolution technology to achieve the required stereochemical purity (>99.5% ee), followed by salt formation with citric acid to produce the final Maropitant citrate form. The entire process is conducted under strict pharmaceutical conditions in dedicated reactors ranging from 500L to 5000L capacity.
Key facility features include:
- ISO Class 7 (Class 10,000) cleanroom environments for final-stage processing and packaging
- Automated process control systems with real-time monitoring of critical process parameters
- Dedicated solvent recovery and waste treatment systems ensuring environmental compliance
- Annual production capacity exceeding 2 metric tons of Maropitant citrate API
- Segregated production suites preventing cross-contamination with other APIs
Our process development team continuously optimizes reaction conditions, achieving batch-to-batch consistency with yields exceeding 85% at the final step. All critical intermediates undergo in-process testing before advancing to subsequent synthesis stages.
Quality Standards & Multi-Pharmacopeial Compliance
Our Maropitant citrate API is manufactured to meet or exceed EP and USP specifications. Every batch undergoes complete analytical testing using validated methods:
| Parameter | Specification | Test Method |
|---|---|---|
| Appearance | White to off-white crystalline powder | Visual |
| Identification | Positive by IR, HPLC, MS | IR/HPLC/MS |
| Assay (anhydrous basis) | ≥98.5% | HPLC |
| Chiral Purity | ≥99.5% ee | Chiral HPLC |
| Related Substances (total) | ≤0.5% | HPLC |
| Any Single Impurity | ≤0.10% | HPLC |
| Residual Solvents | Meets ICH Q3C | GC-HS |
| Heavy Metals | ≤10 ppm | ICP-MS |
| Water Content | ≤0.5% | Karl Fischer |
| Particle Size (D90) | ≤50 μm (micronized grade available) | Laser Diffraction |
Regulatory Documentation
We provide a complete regulatory support package for Maropitant citrate, facilitating streamlined registration in target markets worldwide. Documentation includes:
- Complete Drug Master File (DMF) available for cross-reference in US, EU, and other jurisdictions
- Certificate of Quality Compliance issued by China NMPA
- CEP (Certificate of Suitability) application support for European Pharmacopoeia compliance
- Full validation reports covering process validation, analytical method validation, and cleaning validation
- Stability data (ICH Q1A conditions) with 36-month long-term and 6-month accelerated data
- Detailed impurity profile with synthesis and characterization of all specified impurities
- Environmental and occupational health safety data sheets
Our regulatory affairs team works directly with customers to support veterinary drug applications in the US (FDA CVM), EU (EMA), and other regulatory jurisdictions, providing technical responses and additional data as needed during the review process.
Packaging & Logistics
Maropitant citrate is packaged in pharmaceutical-grade containers designed to maintain product integrity during international shipping:
- Primary packaging: Double-layer polyethylene bags with tamper-evident seals
- Secondary packaging: Fiber drums (25 kg net) or aluminum foil-lined boxes (1 kg, 5 kg) per customer specification
- Desiccant included for moisture-sensitive applications
- Storage conditions: 2-8°C recommended; shipped in temperature-controlled containers for intercontinental transit
- Shelf life: 36 months from date of manufacture when stored as directed
We maintain relationships with major freight forwarders experienced in pharmaceutical cold-chain logistics, offering DDP, CIF, and FOB Incoterms. Typical lead time from order confirmation to port of departure is 15-20 business days for stock items.
Competitive Pricing & Supply Reliability
As a vertically integrated manufacturer with in-house production of key starting materials, we offer Maropitant citrate at highly competitive pricing without compromising quality. Our cost advantages derive from:
- Backward integration reducing dependence on external intermediate suppliers
- Economies of scale with multi-ton annual production capacity
- Optimized synthetic route with high overall yield and efficient solvent recovery
- Strategic raw material procurement with long-term supply agreements
We support flexible order quantities from 100g sample orders to multi-ton commercial supply agreements, with dedicated key account managers assigned to each customer. Long-term supply agreements with quarterly pricing reviews are available for qualified customers, providing budget predictability and guaranteed allocation during periods of high demand.
Contact our export sales team today for a competitive quotation on Maropitant citrate API, including sample availability and technical documentation packages tailored to your regulatory requirements.